血清CA19-9、CEA、CA125和CA242在同步放化疗治疗的胰腺癌患者诊断及预后中的应用价值

Applicative Value of Serum CA19-9, CEA, CA125 and CA242 in Diagnosis and Prognosis for Patients with Pancreatic Cancer Treated by Concurrent Chemoradiotherapy.

作者信息

Gu Yu-Lei, Lan Chao, Pei Hui, Yang Shuang-Ning, Liu Yan-Fen, Xiao Li-Li

机构信息

Emergency Department, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China E-mail :

出版信息

Asian Pac J Cancer Prev. 2015;16(15):6569-73. doi: 10.7314/apjcp.2015.16.15.6569.

DOI:10.7314/apjcp.2015.16.15.6569

PMID:26434876

Abstract

OBJECTIVE

To evaluate the application value of serum CA19-9, CEA, CA125 and CA242 in diagnosis and prognosis of pancreatic cancer cases treated with concurrent chemotherapy.

MATERIALS AND METHODS

52 patients with pancreatic cancer, 40 with benign pancreatic diseases and 40 healthy people were selected. The electrochemiluminescence immunoassay method was used for detecting levels of CA19-9, CEA and CA125, and a CanAg CA242 enzyme linked immunoassay kit for assessing the level of CA242. The Kaplan-Meier method was used for analyzing the prognostic factors of patients with pancreatic cancer. The Cox proportional hazard model was applied for analyzing the hazard ratio (HR) and 95% confidential interval (CI) for survival time of patients with pancreatic cancer.

RESULTS

The levels of serum CA19-9, CEA, CA125 and CA242 in patients with pancreatic cancer were significantly higher than those in patients with benign pancreatic diseases and healthy people (P<0.001). The sensitivity of CA19-9 was the highest among these, followed by CA242, CA125 and CEA. The specificity of CA242 is the highest, followed by CA125, CEA and CA19-9. The sensitivity and specificity of joint detection of serum CA19-9, CEA, CA125and CA242 were 90.4% and 93.8%, obviously higher than single detection of those markers in diagnosis of pancreatic cancer. The median survival time of 52 patients with pancreatic cancer was 10 months (95% CI7.38912.611).. Patients with the increasing level of serum CA19-9, CEA, CA125, CA242 had shorter survival times (P=0.047. 0.043, 0.0041, 0.029). COX regression analysis showed that CA19-9 was an independent prognostic factor for patients with pancreatic cancer (P=0.001, 95%CI 2.59138.243).

CONCLUSIONS

The detection of serum tumor markers (CA19.9, CEA, CA125 and CA242) is conducive to the early diagnosis of pancreatic cancer and joint detection of tumor markers helps improve the diagnostic efficiency. Moreover, CA19-9 is an independent prognostic factor for patients with pancreatic cancer.

摘要

目的

评估血清CA19-9、癌胚抗原（CEA）、CA125和CA242在同步化疗的胰腺癌病例诊断及预后中的应用价值。

材料与方法

选取52例胰腺癌患者、40例胰腺良性疾病患者和40例健康人。采用电化学发光免疫分析法检测CA19-9、CEA和CA125水平，用CanAg CA242酶联免疫分析试剂盒评估CA242水平。采用Kaplan-Meier法分析胰腺癌患者的预后因素。应用Cox比例风险模型分析胰腺癌患者生存时间的风险比（HR）及95%置信区间（CI）。

结果

胰腺癌患者血清CA19-9、CEA、CA125和CA242水平显著高于胰腺良性疾病患者和健康人（P<0.001）。其中CA19-9的敏感性最高，其次是CA242、CA125和CEA。CA242的特异性最高，其次是CA125、CEA和CA19-9。血清CA19-9、CEA、CA125和CA242联合检测的敏感性和特异性分别为90.4%和93.8%，明显高于这些标志物单项检测在胰腺癌诊断中的水平。52例胰腺癌患者的中位生存时间为10个月（95%CI 7.38912.611）。血清CA19-9、CEA、CA125、CA242水平升高的患者生存时间较短（P=0.047、0.043、0.0041、0.029）。COX回归分析显示，CA19-9是胰腺癌患者的独立预后因素（P=0.001，95%CI 2.59138.243）。